{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"3.0","value":"1.8"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"3.3","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"444"}],"units":"Participants"}],"description":"Patients who died during treatment or within 30 days after the end of treatment","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin","id":"OG000","title":"RT + Cisplatin"},{"description":"Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin plus cetuximab","id":"OG001","title":"RT + Cisplatin + Cetuximab"}],"paramType":"NUMBER","populationDescription":"Randomized eligible patients with follow-up data","reportingStatus":"POSTED","timeFrame":"From start of treatment to 30 days after the end of treatment","title":"Rate of Deaths ≤ 30 Days After Discontinuation of Protocol Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}